Gilead Sciences has announced the promotion of James R. Meyers to executive vice president, Worldwide Commercial Operations, with responsibility for commercial operations in North America, Europe and Japan. Meyers will become an officer of the company and member of Gilead’s senior leadership team.
Mr. Meyers joined Gilead in 1996 as a regional sales director and has been the senior vice president of North American Commercial Operations since 2007. In his 20 years at Gilead, Meyers has been instrumental in building out the company’s commercial operations in North America, including leading successful product launches in HIV, oncology, cardiovascular, respiratory and liver diseases. Prior to Gilead, Mr. Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA.
“Jim has demonstrated a remarkable ability to navigate the complexities of commercial operations, ensuring we reach diverse audiences with information about Gilead’s medicines and ultimately that we make those medicines accessible to people in need,” said Kevin Young CBE, chief operating officer, Gilead Sciences. “I am confident that as Gilead’s portfolio of products continues to grow, Jim’s leadership and exceptional track record make him ideally suited to lead our global commercial organization.”